Publications
>
Review

Organoids and colorectal cancer

Publicated to:Cancers. 13 (11): 2657- - 2021-06-01 13(11), DOI: 10.3390/cancers13112657

Authors: Barbachano, Antonio; Fernandez-Barral, Asuncion; Bustamante-Madrid, Pilar; Prieto, Isabel; Rodriguez-Salas, Nuria; Larriba, Maria Jesus; Munoz, Alberto

Affiliations

Centro de Investigación Biomedica en Red Cáncer (CIBERONC) - Author
Hospital Universitario La Paz - Author
Instituto de Investigacion Sanitaria La Fe - Author
Universidad Autónoma de Madrid - Author
‎ Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain - Author
‎ Hosp Univ La Paz IdiPAZ, Inst Invest Sanitaria, Madrid 28046, Spain - Author
‎ Hosp Univ La Paz, Serv Cirugia Gen, Madrid 28046, Spain - Author
‎ Hosp Univ La Paz, Serv Oncol Med, Madrid 28046, Spain - Author
‎ Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain - Author
See more

Abstract

Organoids were first established as a three‐dimensional cell culture system from mouse small intestine. Subsequent development has made organoids a key system to study many human physiological and pathological processes that affect a variety of tissues and organs. In particular, organoids are becoming very useful tools to dissect colorectal cancer (CRC) by allowing the circumvention of classical problems and limitations, such as the impossibility of long‐term culture of normal intestinal epithelial cells and the lack of good animal models for CRC. In this review, we describe the features and current knowledge of intestinal organoids and how they are largely contributing to our better understanding of intestinal cell biology and CRC genetics. Moreover, recent data show that organoids are appropriate systems for antitumoral drug testing and for the personalized treatment of CRC patients.

Keywords
cancercoloncolorectalorganoidspatient-derived organoid/pdoCancerColonColorectalConsensus molecular subtypesEpithelial organoidsHuman colonIn-vitroIntestinal organoidsLgr5(+) stem-cellsOn-a-chipOrganoidsPatient-derived organoidPatient-derived organoid/pdoPatient-derived organoidsPatient-derived tumor organoidPatient-derived tumor organoid/pdtoPatient‐derived organoid/pdoPatient‐derived tumor organoid/pdtoPdoPdtoPreclinical modelsT-cell

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancers due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 60/245, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 3.09. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 3.36 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 11.73 (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-18, the following number of citations:

  • WoS: 34
  • Scopus: 40
  • Europe PMC: 27
  • OpenCitations: 39
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-18:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 149.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 148 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 20.3.
  • The number of mentions on the social network X (formerly Twitter): 18 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/704577
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (BARBACHANO BECERRIL, ANTONIO) and Last Author (Munoz A).